PLX Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of --. Protalix BioTherapeutics's return on equity of 10.9% beat Perspective Therapeutics's return on equity of --.

Protalix BioTherapeutics has a consensus price target of $14.00, signalling upside risk potential of 797.44%. On the other hand Perspective Therapeutics has an analysts' consensus of $13.8214 which suggests that it could grow by 475.89%. Given that Protalix BioTherapeutics has higher upside potential than Perspective Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Perspective Therapeutics.

Protalix BioTherapeutics has a beta of -0.048, which suggesting that the stock is 104.824% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $10.1M, which are larger than Perspective Therapeutics quarterly revenues of --. Protalix BioTherapeutics's net income of -$3.6M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 39.00x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.19x versus 16.92x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of -30140.49%. Protalix BioTherapeutics's return on equity of 10.9% beat Inovio Pharmaceuticals's return on equity of -125.47%.

Protalix BioTherapeutics has a consensus price target of $14.00, signalling upside risk potential of 797.44%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.50 which suggests that it could grow by 275%. Given that Protalix BioTherapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Inovio Pharmaceuticals.

Protalix BioTherapeutics has a beta of -0.048, which suggesting that the stock is 104.824% less volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 1.401, suggesting its more volatile than the S&P 500 by 40.133%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $10.1M, which are larger than Inovio Pharmaceuticals quarterly revenues of $65.3K. Protalix BioTherapeutics's net income of -$3.6M is higher than Inovio Pharmaceuticals's net income of -$19.7M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 39.00x while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.19x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

NexGel has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of -25.37%. Protalix BioTherapeutics's return on equity of 10.9% beat NexGel's return on equity of -59.55%.

Protalix BioTherapeutics has a consensus price target of $14.00, signalling upside risk potential of 797.44%. On the other hand NexGel has an analysts' consensus of $6.00 which suggests that it could grow by 175.23%. Given that Protalix BioTherapeutics has higher upside potential than NexGel, analysts believe Protalix BioTherapeutics is more attractive than NexGel.

Protalix BioTherapeutics has a beta of -0.048, which suggesting that the stock is 104.824% less volatile than S&P 500. In comparison NexGel has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NexGel offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. NexGel pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $10.1M, which are larger than NexGel quarterly revenues of $2.8M. Protalix BioTherapeutics's net income of -$3.6M is lower than NexGel's net income of -$712K. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 39.00x while NexGel's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.19x versus 1.48x for NexGel. Usually stocks with elevated PS ratios are considered overvalued.

Sangamo Therapeutics has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of -475.33%. Protalix BioTherapeutics's return on equity of 10.9% beat Sangamo Therapeutics's return on equity of -269.87%.

Protalix BioTherapeutics has a consensus price target of $14.00, signalling upside risk potential of 797.44%. On the other hand Sangamo Therapeutics has an analysts' consensus of $4.10 which suggests that it could grow by 804.88%. Given that Sangamo Therapeutics has higher upside potential than Protalix BioTherapeutics, analysts believe Sangamo Therapeutics is more attractive than Protalix BioTherapeutics.

Protalix BioTherapeutics has a beta of -0.048, which suggesting that the stock is 104.824% less volatile than S&P 500. In comparison Sangamo Therapeutics has a beta of 1.456, suggesting its more volatile than the S&P 500 by 45.634%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sangamo Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Sangamo Therapeutics pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $10.1M, which are larger than Sangamo Therapeutics quarterly revenues of $6.4M. Protalix BioTherapeutics's net income of -$3.6M is higher than Sangamo Therapeutics's net income of -$30.6M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 39.00x while Sangamo Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.19x versus 1.51x for Sangamo Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.